Chiral and stereoisomeric impurity standards

Four kinds of stereochemical impurity, not one

Chirality is discussed as if it were a single topic. In a specification it is at least four, and each one needs a different standard:

• Enantiomer. The mirror image of the drug substance. Same connectivity, every stereocentre inverted. It is the impurity a chiral method exists to separate, and the one most often bought as a catalogue item.
• Diastereomer. One stereocentre inverted while the others are unchanged. Not a mirror image, so it has different physical properties and usually separates on an achiral column as well. In a molecule with two or more stereocentres there are several of these, and they are distinct substances rather than variants of one impurity.
• Epimer. A diastereomer differing at exactly one centre, typically the one adjacent to a carbonyl or introduced late in the synthesis. Epimerisation is often a degradation pathway rather than a carry-through from the route, which changes what the standard is for.
• Geometric isomer. E/Z at a double bond, or cis/trans on a ring. Not chirality in the strict sense, but it belongs in the same conversation because it is also a spatial arrangement that a method has to resolve and a certificate has to state.

A supplier listing "the enantiomer" of a molecule with three stereocentres has told you almost nothing. The question is which one.

What a stereochemical standard has to state

Five facts decide whether the material can do the job it was bought for.

• Absolute configuration, drawn. Not "the (S)-isomer" in the name alone, but a structure with wedges and dashes. Names and drawings disagree more often than anyone expects, and when they do, the drawing is what a chemist reads.
• Chiral purity of the standard itself, with the method. A standard that is 97 percent enantiomerically pure cannot demonstrate that a method resolves 0.1 percent of the opposite enantiomer: the impurity is inside the reference. The number and the method behind it must both be on the certificate.
• Salt and solvate form. An enantiomer standard supplied as the free base, weighed against a hydrochloride drug substance, moves every retention time and every response factor in the method.
• Whether the value is a ratio or an excess. Enantiomeric excess, enantiomeric ratio and area percent on a chiral method are three different quantities and they are not interchangeable.
• Storage and equilibration. Chiral standards in solution can racemise, and some racemise faster in light or at room temperature than the solid does.

How chiral purity is actually measured

Almost always by chromatography on a chiral stationary phase, by HPLC or by supercritical fluid chromatography. The columns are built on polysaccharide derivatives - cellulose and amylose carbamates and benzoates are the workhorses - or on macrocyclic antibiotics, cyclodextrins, or synthetic polymers with a defined cavity. Which one resolves a given molecule is not predictable from the structure, which is why method development on a chiral separation is empirical: screen several columns and several modifier compositions rather than tune one.

Three practical points that decide whether the number on the certificate means anything:

• Elution order must be established. A chromatogram with two peaks does not say which is the drug and which is the impurity. The order is fixed by spiking with the individual standards, and it can invert when the mobile phase or the column changes.
• Detection is usually UV, and the two enantiomers have identical UV spectra. That is convenient for response factor, and unhelpful for identification: peak identity rests entirely on retention and on the spiking experiment.
• Polarimetry is a weak substitute. Specific rotation is a bulk property, linear only over a small range, sensitive to concentration, solvent and temperature, and blind to a racemic contaminant that also rotates the plane. It cannot replace a chromatographic enantiomeric purity determination.

Where a chiral standard is used, and how it fails

Three uses dominate: peak identification in the enantiomeric purity method, calibration of that method when the limit is tight, and identification of a degradant that turns out to be an epimer.

The characteristic failure is a standard whose own stereochemical quality is undocumented. It passes identity, it elutes where expected, and it silently sets the floor of the method: a limit of 0.1 percent cannot be demonstrated with a standard carrying 0.5 percent of the opposite enantiomer. The second failure is a mismatch between the configuration on the vial and the configuration in the method - a drawing error that surfaces as an unexplained extra peak in a validation run.

Chiral switches change the standard set

When a racemate is replaced by a single enantiomer, the impurity logic inverts. In the racemic product the two enantiomers were the substance; in the single-enantiomer product one of them becomes a specified impurity with a limit, and the old racemate standard is now the wrong tool. The standard that controls the new specification is the opposite enantiomer, and it has to be available in the same salt form as the drug substance, at a stated chiral purity, with the elution order fixed.

The same inversion happens in the other direction during development, when a programme carries a racemate and a single enantiomer in parallel. One set of standards cannot serve both specifications, and a laboratory that buys "the chiral impurity" without saying which programme it is for usually ends up with material at the wrong configuration.

Sample preparation can create the impurity you are measuring

Some of the stereochemical impurity on a chromatogram was not in the drum. Epimerisation and racemisation occur in solution, and they are accelerated by exactly the conditions a sample preparation might use: base, heat, prolonged standing, a protic solvent, or a derivatisation step that goes through an enolisable intermediate. The methods most exposed are those for compounds with an acidic methine next to a carbonyl, a thioacetal, or an activated benzylic centre.

The practical consequence for standards is that a working solution has its own shelf life, often shorter than the analyst assumes, and that a blank spiked and left on the autosampler for the length of a run is a more honest check than a freshly prepared one. Where the standard is supplied as a solution, the certificate should say what it is dissolved in and for how long it is stated to be stable; where it is supplied as a solid, the risk moves to the balance and to the desiccator.

What to ask before you buy

• Which stereoisomer is this, stated as absolute configuration and shown as a drawing with stereobonds?
• What is its own enantiomeric or diastereomeric purity, and by which method and column?
• Is the certificate value an excess, a ratio or an area percent?
• Which salt or solvate form is supplied, and what is the counter-ion?
• For a multi-centre molecule: are the other diastereomers available, and are they supplied individually or as a mixture?
• Has the elution order been established against the drug substance, and is that stated?

None of this is exotic. It is the same list a reviewer will use when the method is submitted, and it is far cheaper to settle at purchase than at validation. Chiral items sit alongside the other related substances in the same parent-drug grouping, so the impurity standards index is the place to see what exists for a given active substance, and the certificate fields guide covers the parts of the document that are common to every standard, chiral or not.